OSL 1.4 cents $ 52 million market cap approx
G-BA updates to come soon , R & D refund expected to be around $ 1 million and they are well funded regardless and have enough funds until end of next calendar year , further expansion into markets. Revenue is improving , further approvals to come , clinical trial updates including TGA , FDA. EU MDR approval expected this month which the TGA considers the data in a application for regulatory approval in Australia.
This will surpass a $100 million market cap and the stock price could overshoot to the upside as we have seen so many times with small caps especially with momentum and sentiment. As per chart supply should be far lower once this stock price zone is breached. Well funded with a strong team and the best it has looked in terms of FA and TA in a very long time. Accumulation in process around the current stock price before a Blitzkrieg move forward.
